Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
31 Cards in this Set
- Front
- Back
|
gastric MALT lymphomas are associated with
|
H Pylori infections- treat infection
|
|
|
4 infections associated with NHL
|
1) Human T-cell leukemia virus type I
2) EBV 3) HIV 4) H Pylori |
|
|
biopsy method for diagnosis of NHL
|
excisional biopsy- FNA is inadequate
|
|
|
doxorubicin adjustment w/ MUGA in CHOP
|
LVEF<=30%, do not start
>30% to <50%, repeat MUGA @ each dosing >=50%, repeat MUGA after 250-300mg/m2 |
|
|
doxorubicin adjustment w/ bilirubin in CHOP
|
Tbili 1.5-3, decrease 50%
Tbili 3.1-5, decrease 75% Tbili >5, omit |
|
|
lifetime cumulative risk w/ doxorubicin boluses
|
550 mg/m2
|
|
|
vincristine adjustment w/ bilirubin in CHOP
|
Tbili 1.5-3, decrease 50%
Tbili >3, omit |
|
|
gold standard for NHL pts who relapse after conventional chemo
|
high dose chemo followed by autologous SCT
|
|
|
antigen target of rituximab
|
CD20
|
|
|
relapsed mantle cell lymphomas can be treated with
|
bortezomib 1.3mg/m2 d1,4,8,11 Q21D
|
|
|
malignant cell in Hodgkin's
|
Reed-Sternberg cell- binucleated and express CD30 and CD15
|
|
|
virus risk factors in Hodgkin's
|
1) EBV
2) mononucleosis 3) HIV |
|
|
proper biopsy to diagnose HL
|
excisional lymph node biopsy since architecture of the lymph node is necessary. FNA inadequate.
|
|
|
7 negative prognostic factors at dx of HL:
|
1) albumin <4g/dl
2) Hgb < 10.5 g/dl 3) male sex 4) stage IV 5) age >=45 6) WBC >=15,000 7) lymphopenia <600 or <8% WBC |
|
|
for relapses after RT for early HL, consider chemo with
|
doxorubicin containing regimens more effective than MOPP
|
|
|
bleomycin dose adjustments in ABVD
|
CrCl<60, reduce dose
CrCl<30, not recommended |
|
|
to reduce risk of hypersensitivity in lymphoma pts, do this w/ bleo
|
1-2 U test dose
|
|
|
major toxicity of bleomycin
|
pulmonary toxicity
|
|
|
cumulative max dose of bleomycin
|
400 units
|
|
|
vinblastine dose modification in ABVD for HL
|
Tbili 1.5-3, decrease by 50%
Tbili >3, omit |
|
|
dacarbazine dose reduction in ABVD for HL
|
CrCl<60, dose reduce
|
|
|
cell responsible for multiple myeloma
|
plasma cell
|
|
|
MM stage where Beta-2 microglobulin <3.5
|
stage I
|
|
|
MM stage where albumin >=3.5
|
stage 1
|
|
|
3 potential regimens for induction therapy of MM
|
1) melphalan/prednisone+/-bortezomib
2) VAD 3) thalidomide/dex |
|
|
complication of thalidomide/dex tx for MM
|
thromboembolic events
|
|
|
most common adverse effects of bortezomib
|
nausea/diarrhea, fatigue, thrombocytopenia, sensory neuropathy
|
|
|
strongest predictors of favorable outcome in MM
|
1) low Beta-2 microglobulin
2) low C-reactive protein |
|
|
use of high dose melphalan in MM patients in renal failure
|
renal failure is not a contraindication of HD therapy
|
|
|
1st line agent for Peripheral T-Cell Lymphoma
|
CHOP
|
|
|
2nd line agent for Peripheral T-Cell Lymphoma
|
pralatrexate
|
